The fish insulin/insulin-like progress issue (IGF) pathway has weak management over carbohydrate metabolism. To know the molecular foundation for the metabolic variety, we characterised the forkhead field transcription issue O1A (FoxO1A), a downstream goal of the insulin/IGF pathway, in torafugu Takifugu rubripes. The cloned torafugu FoxO1A cDNA contained all conserved options crucial for its transcriptional exercise and a singular unspliced intron encoding a poly-glutamine stretch. Torafugu FoxO1A confirmed the IGF-dependent nuclear exclusion and in vitro binding to the well-conserved FoxO1 binding website, DAF-16-binding ingredient (DBE), however did not bind to the insulin-responsive ingredient by which mammalian FoxO1 mediates insulin results.
The next in silico genomic screening offered a listing of 587 potential torafugu FoxO1A goal genes containing the DBE. Some carbohydrate metabolic genes regulated by FoxO1 in mammals weren’t included within the record. We additional recognized about 250 potential fish FoxO1 goal genes by integrating outcomes of the DBE screening towards fish metagenome that contained 262 species. Neuronal processes gave the impression to be the widespread main perform of fish FoxO1, though additional annotation of the potential goal genes is required. These outcomes present part of the molecular foundation underlying the weak affiliation between the insulin/IGF pathway and carbohydrate metabolism in fish. Strategies that allow the development of recombinant DNA molecules are important instruments for organic analysis and biotechnology. Golden Gate cloning is used for meeting of a number of DNA fragments in an outlined linear order in a recipient vector utilizing a one-pot meeting process. Golden Gate cloning relies on using a sort IIS restriction enzyme for digestion of the DNA fragments and vector.
As a result of restriction websites for the sort IIS enzyme used for meeting have to be current on the ends of the DNA fragments and vector however absent from all inside sequences, particular care have to be taken to arrange DNA fragments and the recipient vector with a construction appropriate for meeting by Golden Gate cloning. On this article, protocols are introduced for preparation of DNA fragments, modules, and vectors appropriate for Golden Gate meeting cloning. Extra protocols are introduced for meeting of outlined components in a transcription unit, in addition to the stitching collectively of a number of transcription items into multigene constructs by the modular cloning (MoClo) pipeline.
Golden Gate Cloning-Suitable DNA Replicon/2A-Mediated Polycistronic Vectors for Crops
The expression of a number of proteins and high-throughput vector meeting system are extremely related within the area of plant genetic engineering and artificial biology. Deployment of the self-cleaving 2A peptide that mediates polycistronic gene expression has been an efficient technique for multigene expression, because it minimizes points in coordinated transgene regulation and trait staking in crops. Nonetheless, environment friendly vector meeting programs optimized for 2A peptide-mediated polycistronic expression are presently unavailable. Moreover, it’s unclear whether or not protein expression ranges are influenced by the transgene place within the polycistronic expression cassette.
On this article, we current Golden Gate cloning-compatible modular programs permitting speedy and versatile development of polycistronic expression vectors relevant for crops. The genetic modules comprised 2A peptides (T2A and P2A)-linked tricistron expression cassette and its acceptor backbones, named pGO-DV1 and pGO-DV2. Whereas each acceptor backbones had been binary T-DNA vectors, pGO-DV2 was specifically designed to perform as a DNA replicon enhancing gene expression ranges. Utilizing the Golden Gate cloning, a set of six tricistronic vectors was constructed, whereby three transgenes encoding fluorescent proteins (mCherry, eYFP, and eGFP) had been combinatorially positioned alongside the expression cassette in every of the binary vectors.
Transient expression of the assemble in tobacco leaves revealed that the expression ranges of three fluorescent proteins had been comparable one another whatever the gene positions within the tricistronic expression cassette. pGO-DV2-based constructs had been in a position to improve protein expression stage by as much as 71%, as in comparison with pGO-DV1-based constructs.
Forkhead transcription factor O1 (FoxO1) in torafugu pufferfish Takifugu rubripes: Molecular cloning, in vitro DNA binding, and target gene screening in fish metagenome
World Vacationers: DNA Barcoding Unmasks the Origin of Cloning Asteroid Larvae from the Caribbean
AbstractThe id of untamed cloning sea star larvae has been a thriller since they had been first documented within the Caribbean. Probably the most generally collected cloning species was thought to belong to the Oreasteridae, on the premise of similarity with sequences from Oreaster reticulatus and Oreaster clavatus. This larval type has not too long ago been linked to a uncommon benthic juvenile. As a part of two bigger DNA barcoding tasks, we collected cloning asteroid larvae from the Caribbean coast of Panama and in contrast them to a big reference database of tropical echinoderms.
 Antibody) Melanoma Marker(PNL2) Antibody |
|||
| BNUB0894-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC040894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC040894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC550894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC550894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC610894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC610894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC470894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC470894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC050894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC050894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC400894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC400894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC430894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC430894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC800894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC800894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCP0894-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCR0894-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCA0894-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCAP0894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCAP0894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCB0894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCB0894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCH0894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNCH0894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC880894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC880894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC940894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC940894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC680894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC680894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC700894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC700894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC810894-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(PNL2) Antibody |
|||
| BNC810894-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
 Anti-Melanoma Marker antibody |
|||
| STJ16100745 | St John's Laboratory | 1 mL | EUR 352 |
 Antibody) Melanoma Marker(KBA.62) Antibody |
|||
| BNUM0895-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), 1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNUB0895-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNUB0895-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC040895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC040895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF405S conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC550895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC550895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF555 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC610895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC610895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF660R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC470895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC470895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF647 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC050895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC050895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF405M conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC400895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC400895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF640R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC430895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC430895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF543 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC800895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC800895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF680 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCP0895-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), PerCP conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCR0895-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), RPE conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCA0895-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), APC conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCAP0895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCAP0895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCB0895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCB0895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Biotin conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCH0895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNCH0895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC880895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC880895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF488A conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC940895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC940895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF594 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC680895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC680895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF568 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC700895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC700895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF770 conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC810895-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF680R conjugate, Concentration: 0.1mg/mL |
|||
|
Melanoma Marker(KBA.62) Antibody |
|||
| BNC810895-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Melanoma Marker(KBA.62), CF680R conjugate, Concentration: 0.1mg/mL |
|||
 (S1/61) Antibody) S100A (Melanoma Marker) (S1/61) Antibody |
|||
| BNUM1695-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against S100A (Melanoma Marker) (S1/61), 1mg/mL |
|||
 (SOX10/2311R) Antibody) SOX10 (Melanoma Marker) (SOX10/2311R) Antibody |
|||
| BNCR2311-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/2311R), RPE conjugate, Concentration: 0.1mg/mL |
|||
 (rSOX10/1074) Antibody) SOX10 (Melanoma Marker) (rSOX10/1074) Antibody |
|||
| BNCR2312-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (rSOX10/1074), RPE conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) Melanoma Marker(HMB45 + A103 + T311) Antibody |
|||
| BNUB0702-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Melanoma Marker(HMB45 + A103 + T311), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(HMB45 + A103 + T311) Antibody |
|||
| BNUB0702-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Melanoma Marker(HMB45 + A103 + T311), Concentration: 0.2mg/mL |
|||
 Antibody) Melanoma Marker(DT101+ BC199 + HMB45) Antibody |
|||
| BNUB0703-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Melanoma Marker(DT101+ BC199 + HMB45), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(DT101+ BC199 + HMB45) Antibody |
|||
| BNUB0703-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Melanoma Marker(DT101+ BC199 + HMB45), Concentration: 0.2mg/mL |
|||
 (SOX10/991) Antibody) SOX10 (Melanoma Marker) (SOX10/991) Antibody |
|||
| BNUB0991-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/991), 1mg/mL |
|||
 (SOX10/1074) Antibody) SOX10 (Melanoma Marker) (SOX10/1074) Antibody |
|||
| BNUB1074-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/1074), 1mg/mL |
|||
|
S100A (Melanoma Marker) (S1/61) Antibody |
|||
| BNUB1695-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against S100A (Melanoma Marker) (S1/61), Concentration: 0.2mg/mL |
|||
|
S100A (Melanoma Marker) (S1/61) Antibody |
|||
| BNUB1695-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against S100A (Melanoma Marker) (S1/61), Concentration: 0.2mg/mL |
|||
 (TYR/2024R) Antibody) Tyrosinase (Melanoma Marker) (TYR/2024R) Antibody |
|||
| BNUB2024-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against Tyrosinase (Melanoma Marker) (TYR/2024R), Concentration: 0.2mg/mL |
|||
|
Tyrosinase (Melanoma Marker) (TYR/2024R) Antibody |
|||
| BNUB2024-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against Tyrosinase (Melanoma Marker) (TYR/2024R), 1mg/mL |
|||
|
Tyrosinase (Melanoma Marker) (TYR/2024R) Antibody |
|||
| BNUB2024-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against Tyrosinase (Melanoma Marker) (TYR/2024R), Concentration: 0.2mg/mL |
|||
|
SOX10 (Melanoma Marker) (SOX10/2311R) Antibody |
|||
| BNUB2311-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/2311R), Concentration: 0.2mg/mL |
|||
|
SOX10 (Melanoma Marker) (SOX10/2311R) Antibody |
|||
| BNUB2311-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/2311R), 1mg/mL |
|||
|
SOX10 (Melanoma Marker) (SOX10/2311R) Antibody |
|||
| BNUB2311-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (SOX10/2311R), Concentration: 0.2mg/mL |
|||
|
SOX10 (Melanoma Marker) (rSOX10/1074) Antibody |
|||
| BNUB2312-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (rSOX10/1074), Concentration: 0.2mg/mL |
|||
|
SOX10 (Melanoma Marker) (rSOX10/1074) Antibody |
|||
| BNUB2312-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (rSOX10/1074), 1mg/mL |
|||
|
SOX10 (Melanoma Marker) (rSOX10/1074) Antibody |
|||
| BNUB2312-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against SOX10 (Melanoma Marker) (rSOX10/1074), Concentration: 0.2mg/mL |
|||
|
Melanoma Marker(HMB45 + A103 + T311) Antibody |
|||
| BNUM0702-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Melanoma Marker(HMB45 + A103 + T311), 1mg/mL |
|||
|
Melanoma Marker(DT101+ BC199 + HMB45) Antibody |
|||
| BNUM0703-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Melanoma Marker(DT101+ BC199 + HMB45), 1mg/mL |
|||
|
Melanoma Marker(HMB45 + A103 + T311) Antibody |
|||
| BNC040702-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Melanoma Marker(HMB45 + A103 + T311), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Morphological and DNA barcode information from the cytochrome c oxidase subunit I gene demonstrated that Panamanian larvae belonged to the identical operational taxonomic unit as these recovered in earlier research of cloning larvae from the Caribbean. A lot to our shock, sequences from these larvae clearly recognized them as belonging to Valvaster striatus, a species sometimes thought-about to be endemic to the Indo-West Pacific. A lineage of Mithrodia clavigera that happens in each the Caribbean and the Indo-West Pacific additionally has cloning larvae, suggesting that this uncommon life historical past has allowed larvae to move across the Cape of Good Hope and the Benguela upwelling area, which is a barrier to dispersal for many tropical marine invertebrates.